Abstract
The α2-adrenergic receptor antagonist yohimbine was administered to 12 drug-free patients with obsessive compulsive disorder (OCD) and to 12 healthy subjects. Changes in behavior, cardiovascular symptoms, and in plasma levels of cortisol and the norepinephrine metabolite, 3-methoxy-4-hydroxyphenylglycol (MHPG), were assessed. Yohimbine had no significant effect on OCD symptoms. The OCD patients did not differ from healthy controls in their behavioral and MHPG response to yohimbine. In contrast to healthy subjects, OCD patients, like previous reports of depressed and panic disorders patients, had an increased cortisol response to yohimbine. These data suggest it is unlikely that abnormal noradrenergic function plays a primary role in the pathogenesis of OCD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Blombery PA, Kopin IJ, Gordon EK, Markey SP, Ebert MH (1980) Conversion of MHPG to vanillylmandelic acid: Implications for the importance of urinary MHPG. Arch Gen Psychiatry 37:1095–1098
Breier A, Charney DS, Henninger GR (1986) Agoraphobia with panic attacks: Development, diagnostic stability, and course of illness. Arch Gen Psychiatry 43:1029–1036
Bruto V, Beauchamp C, Zacharko RM, Anisman H (1984) Amphetamine-induced perseverative behavior in a radial arm maze following DSP4 or 6-OHDA pretreatment. Psychopharmacology 83:62–69
Cedarbaum JM, Aghajanian GK (1976) Noradrenergic neurons of the locus coeruleus: Inhibition by epinephrine and activation by the alpha-2 antagonist piperoxane. Brain Res 112:413–419
Cedarbaum JM, Aghajanian GK (1977) Catecholamine receptors on locus coeruleus neurons: Pharmacological characterization. Eur J Pharmacol 44:375–385
Charney DS, Redmond DE Jr (1983) Neurobiological mechanisms in human anxiety: Evidence for noradrenergic hyperactivity. Neuropharmacology 22:1531–1536
Charney DS, Heninger GR, Sternberg DE (1982) Assessment of alpha-2 adrenergic autoreceptor function in humans: Effects of oral yohimbine. Life Sci 30, 2033–2041
Charney DS, Heninger GR, Breier A (1984) Noradrenergic function in panic anxiety: Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 41: 751–763
Cohen DJ, Detlor J, Young JG, Shaywitz BA (1980) Clonidine ameliorates Gilles de la Tourette Syndrome. Arch Gen Psychiatry 37:1350–1357
Ellsworth JD, Redmond DE, Roth RH (1982) Plasma and cerebrospinal fluid 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) as indices of brain norepinephrine metabolism in primates. Brain Res 235:115–124
Ganong WF (1980) Neurotransmitters and pituitary function: Regulation of ACTH secretion. Fed Proc 39:2923–2930
Goodman WK, Charney DS (1985) Therapeutic applications and mechanisms of action of monoamine oxidase inhibitor and heterocyclic antidepressant drugs. J Clin Psychiatry 46:6–22
Gorman JM, Liebowitz MR, Fyer AJ, Dillon D, Davies SO, Stein J, Klein DF (1985) Lactate infusions in obsessive-compulsive disorder. Am J Psychiatry 142:864–866
Guy W (1976) ECDEU Assessment Manual for Psychopharmacology: Publication 76–338. Washington, DC, US Department of Health, Education, and Welfare
Insel TR, Murphy DL (1981) The psychopharmacological treatment of obsessive-compulsive disorder: A review. J Clin Psychopharmacol 1:304–311
Insel TR, Mueller EA, Gillin JC, Seiver LJ, Murphy DL (1984) Biological markers in obsessive-compulsive and affective disorders. J Psychiatr Res 4:407–423
Jimerson DC, Ballenger JC, Lake CR, Post RM, Goodwin FK, Kopin IJ (1981) Plasma and CSF MHPG in normals. Psychopharmacol Bull 17:86–87
Karoum F, Mayer-Schwing J, Potkin SG, Wyatt RJ (1977) Presence of free sulfate and glucuronide conjugated MHPG in human brain, cerebrospinal fluid and plasma. Brain Res 125:333–339
Knesevich JW (1982) Successful treatment of obsessive-compulsive disorder with clonidine hydrochloride. Am J Psychiatry 139(3):364–365
Kokkinidis L, Anisman H (1976) Dissociation of the effects of scopolamine and d-amphetamine on a spontaneous alternation task. Pharmacol Biochem Behav 5:293–297
Kopin IJ, Jimerson DC, Markey SP, Ebert MH, Polinsky RJ (1984) Disposition and metabolism of MHPG in humans: Application to studies in depression. Pharmacopsychiatry 17:3–8
Leckman JF, Maas JW (1984) Plasma MHPG: Relationship to brain noradrenergic systems and emerging clinical applications. In: Post RM, Ballenger JC (eds) Neurobiology of mood disorders. Williams & Wilkins, Baltimore
Leckman JF, Detlor J, Harcherik DF, Ort S, Shaywitz BA, Cohen DJ (1985) Short- and long-term treatment of Tourette's syndrome with clonidine: A clinical perspective. Neurology 35:343–351
Price LH, Charney DS, Rubin AL, Heninger GR (1986) Alpha-2 adrenergic receptor function in depression: The cortisol response to yohimbine. Arch Gen Psychiatry 43:849–858
Rasmussen SA, Tsuang MT (1986) Clinical characteristics and family history in DSM-III obsessive-compulsive disorder. Am J Psychiatry 143:317–322
Robins LN, Helzer JI, Weissman MM, Orvaschel H, Gruenberg E, Burke JD Jr, Regier DA (1984) Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 41:949–958
Siever LJ, Insel TR, Jimerson DC, Lake CR, Uhde TW, Aloi J, Murphy DL (1983) Growth hormone response to clonidine in obsessive-compulsive patients. Br J Psychiatry 142:184–187
Steketee G, Foa EB, Grayson JB (1982) Recent advances in the behavioral treatment of obsessive-compulsives. Arch Gen Psychiatry 39:1365–1371
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rasmussen, S.A., Goodman, W.K., Woods, S.W. et al. Effects of yohimbine in obsessive compulsive disorder. Psychopharmacology 93, 308–313 (1987). https://doi.org/10.1007/BF00187248
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00187248